Ozempic, initially a diabetes medication, gained FDA approval in 2021 for weight loss, propelling GLP-1 drugs into the spotlight. Now, 1 in 8 American adults have used these drugs, with expectations of increased usage by 2030. Recent research indicates that GLP-1 drugs may reduce risks of cognitive and addiction disorders yet also present serious side effects. A study evaluating over 2.4 million participants revealed that while these drugs lowered the risks of many health issues, they also heightened the risk of gastrointestinal problems, kidney stones, and acute pancreatitis.
We found that these drugs lowered the risks of 42 health outcomes, including neurocognitive disorders and substance use disorders, while increasing the risks of 19 conditions.
GLP-1 drugs have become key tools in the fight against obesity, with 1 in 8 American adults reportedly having used them for weight management.
Collection
[
|
...
]